Novo Nordisk Clinches UK Pill Approval and US Medicare Win, but Competition Narrows the Path
Published on 06/23/2026 at 20:33 | Redaktion boerse-global.de
Novo Nordisk has pulled off a rare double-catalyst week, securing both a European approval for its oral Wegovy and a landmark US government decision to cover the drug for Medicare patients. The combination of regulatory breakthroughs and legal victories has injected fresh momentum into the stock, which has been grinding lower since its 52-week peak.
Shares ended Tuesday at EUR41.08, a gain of 2.55%, after touching EUR40.93 earlier in the session. That leaves the equity roughly 33% below its 12-month high of EUR61.20 but well off its March low of EUR30.25. The recovery is being supported by two separate buyback programmes — one worth up to DKK 15 billion and a newer tranche of DKK 11.2 billion — under which the company has already repurchased nearly 21 million shares, taking its treasury holding to 0.9% of capital.
On the regulatory front, the UK’s MHRA greenlit the oral formulation of Wegovy — a tablet containing semaglutide — marking its first European approval. The pill, which is easier to administer than injections, opens up a much larger patient pool and will be distributed through a same-day logistics partnership with Amazon. Meanwhile, the US Centers for Medicare & Medicaid Services confirmed that Wegovy will be covered from 1 July 2026, with patients paying just USD 50 a month. That overturns a decades-old prohibition on obesity drug reimbursement by the federal programme and dramatically expands the addressable market.
Legal victories are adding a layer of protection. A South African court granted an injunction against local pharmacy group iDexis, ordering it to stop manufacturing and selling unlicensed semaglutide copycats. The ruling sets a precedent that patent protection extends to the active ingredient itself, not just branded formulations. This comes just as copycat products are emerging elsewhere: India has already seen generic launches, Canada has approved one, and Russia has permitted domestic production until 2027. The patent battle is clearly far from over.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
On the pipeline side, Phase 3 data for the next-generation drug CagriSema showed patients losing 14.2% of body weight, with long-term sugar levels falling by almost 2%. That could provide a strong competitive moat once it reaches the market. But challengers are closing fast. Viking Therapeutics reported Phase 2 results for its candidate VK2735 — a 14.7% weight loss with the injectable and 12.2% with the oral pill — which could prove faster-acting than Novo Nordisk’s first-generation portfolio.
Not all risks are competitive. Researchers at the University of Adelaide flagged concerns over SNAC, the absorption enhancer used in the oral semaglutide tablet. The substance might raise inflammation markers and increase liver weight, potentially drawing scrutiny from regulators down the line. That could slow the rollout or limit prescribing populations.
Technically, the stock is bumping up against the 200-day moving average at EUR41.05. A decisive break above that level would confirm the uptrend, but the relative strength index at 67 suggests the shares are approaching overbought territory. A pullback to the 50-day line at EUR37.33 is a plausible consolidation scenario.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The next major inflection point comes on 5 August 2026, when Novo Nordisk reports second-quarter earnings. Management will need to show that the US reimbursement shift and the UK pill launch are already translating into measurable revenue growth. If the volume from new prescriptions can offset the price erosion from generics and competitor pressure, a fair value of around EUR88 per share becomes attainable. If not, a retest of the March low is still on the table.
Ad
Novo Nordisk Stock: New Analysis - 23 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
